Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.47
USD
|
+2.80%
|
|
-18.33%
|
-80.00%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
425.6
|
128.1
|
215.1
|
43.59
|
-
|
-
|
Enterprise Value (EV)
1 |
276.4
|
27.38
|
134.2
|
-5.71
|
-22.33
|
43.59
|
P/E ratio
|
-6.57
x
|
-2.54
x
|
-3.91
x
|
-0.79
x
|
-0.79
x
|
-0.65
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
205
x
|
404
x
|
-
|
-
|
-
|
-
|
EV / Revenue
|
133
x
|
86.4
x
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-8.17
x
|
-0.53
x
|
-2.31
x
|
0.08
x
|
0.26
x
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
1.41
x
|
1.17
x
|
2.38
x
|
0.78
x
|
0.79
x
|
-
|
Nbr of stocks (in thousands)
|
26,320
|
26,405
|
29,269
|
29,653
|
-
|
-
|
Reference price
2 |
16.17
|
4.850
|
7.350
|
1.470
|
1.470
|
1.470
|
Announcement Date
|
3/10/22
|
3/6/23
|
3/1/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
2.08
|
0.317
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-33.84
|
-51.47
|
-58.09
|
-72.07
|
-84.58
|
-
|
EBIT
1 |
-
|
-33.89
|
-51.74
|
-58.41
|
-75.76
|
-97.1
|
-120.5
|
Operating Margin
|
-
|
-1,629.17%
|
-16,325.88%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-33.84
|
-50.51
|
-53.47
|
-73.8
|
-101.3
|
-122.7
|
Net income
1 |
-17.04
|
-33.54
|
-50.51
|
-53.47
|
-72.98
|
-97.85
|
-118
|
Net margin
|
-
|
-1,612.33%
|
-15,937.39%
|
-
|
-
|
-
|
-
|
EPS
2 |
-4.820
|
-2.460
|
-1.910
|
-1.880
|
-1.850
|
-1.850
|
-2.248
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/13/21
|
3/10/22
|
3/6/23
|
3/1/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.4821
|
0.1896
|
0.1837
|
0.0944
|
0.0384
|
0.00046
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-8.543
|
-11.12
|
-12.93
|
-11.65
|
-13.19
|
-13.99
|
-14.68
|
-13.5
|
-13.93
|
-16.3
|
-17.53
|
-18.63
|
-20.05
|
-21.85
|
-23.31
|
Operating Margin
|
-1,772.01%
|
-5,863.05%
|
-7,036.29%
|
-12,334.3%
|
-34,362.04%
|
-3,040,219.57%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-8.534
|
-11.09
|
-12.9
|
-11.53
|
-12.84
|
-13.25
|
-13.6
|
-12.19
|
-12.6
|
-15.08
|
-16.66
|
-18
|
-19.73
|
-21.66
|
-22.09
|
Net income
1 |
-8.534
|
-10.78
|
-12.9
|
-11.53
|
-12.84
|
-13.25
|
-13.6
|
-12.19
|
-12.6
|
-15.08
|
-16.6
|
-17.8
|
-19.27
|
-20.77
|
-22.09
|
Net margin
|
-1,770.08%
|
-5,688.25%
|
-7,020.34%
|
-12,208.54%
|
-33,466.21%
|
-2,879,469.57%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.4700
|
-0.0500
|
-0.4900
|
-0.4400
|
-0.4900
|
-0.5000
|
-0.5100
|
-0.4300
|
-0.4300
|
-0.5200
|
-0.5050
|
-0.4850
|
-0.4883
|
-0.4250
|
-0.5000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/21
|
3/10/22
|
5/10/22
|
8/10/22
|
11/10/22
|
3/6/23
|
5/4/23
|
8/3/23
|
11/9/23
|
3/1/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
149
|
101
|
80.9
|
49.3
|
65.9
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-50.2%
|
-38%
|
-53.4%
|
-107%
|
-108%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
11.50
|
4.160
|
3.090
|
1.890
|
1.850
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
0.34
|
0.3
|
0.3
|
0.3
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/13/21
|
3/10/22
|
3/6/23
|
3/1/24
|
-
|
-
|
-
|
Last Close Price
1.47
USD Average target price
15.14
USD Spread / Average Target +930.13% Consensus |
1st Jan change
|
Capi.
|
---|
| -80.00% | 43.59M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|